Printer Friendly

Bupropion genetic yanked over bioequivalence.

One of the generic forms of the 300-mg dose of extended-release bupropion is being taken off the market because of evidence indicating that it is not therapeutically equivalent to the brand name version of the antidepressant, according to a Food and Drug Administration notice report posted on Oct. 3.

The affected product is Budeprion XL 300 mg, which is manufactured by Impax Laboratories and marketed by Teva Pharmaceuticals USA.

The product is one of the five generic versions of Wellbutrin XL 300-mg tablets that have been approved by the FDA.

The planned withdrawal of Budeprion XL 300 mg is the result of studies conducted by the company and FDA aimed at addressing reports of reduced efficacy from patients who were switched to generic forms of Wellbutrin XL 300 mg made more than 5 years ago.

These reports were made to the agency "'soon after" the Impax/Teva product was approved in December 2006, and the FDA subsequently determined that the complaints "appeared to be linked to the Impax/Teva products," the statement explained.

None of the other generic versions of the 300-mg dose or the Impax 150-mg bupropion product are affected, the FDA said.

However, the agency recently has requested that the four other manufacturers of generic versions of Wellbutrin XL 300 mg conduct bioequivalence studies of their products and to submit the study results to the FDA by March 2013.

Those four manufacturers of the generic bupropion products are Anchen, Actavis, Watson, and Mylan.

Approval of all the generic versions of 300 mg extended-release bupropion was based on studies establishing that the 150-mg strengths were bioequivalent to the 150-mg dose of the brand-name product, according to the FDA guidance at that time.

But the Food and Drug Administration "has determined that this approach is no longer appropriate" to establish bioequivalence and "is revising its guidance to industry for how to conduct premarket bioequivalence studies in generic bupropion products."

The bioequivalence problem was confirmed in an FDA-sponsored study conducted in 2010 comparing the bioequivalence of the Impax/Teva product to Wellbutrin XL 300 mg in 24 healthy adults.

That study determined that the generic tablets "fail to release bupropion into the blood at the same rate and to the same extent as Wellbutrin XL 300 mg,'" according to the statement from the agency.

At the request of the Food and Drug Administration, Impax/Teva had started a study comparing the bioequivalence of the 300-mg product with the brand-name product.

That study will include patients who had reported the problem of reduced efficacy after the switch to the generic product.

But the company was unable to recruit enough patients and terminated the study in late 2011.

Impax and Teva have stopped shipping this product.

The FDA notice is available at www.fda, gov /Drugs / DrugSafety / PostmarketDrugSafetylnformation forPatientsandProviders / ucm3 22161.htm. Health care professionals and patients should report problems associated with drugs to the FDA MedWatch program at www.fda.gov /medwatch or by calling 800-332-1088.

COPYRIGHT 2012 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:MENTAL HEALTH
Author:Mechcatie, Elizabeth
Publication:Family Practice News
Date:Oct 15, 2012
Words:494
Previous Article:High-dose vitamin D didn't curb respiratory infections.
Next Article:Headache, musculoskeletal pain travel together: patients with chronic musculoskeletal pain were 1.8 times more likely to develop chronic headaches.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |